Duloxetine
Product Images NDC 68788-9301

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-9301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap Usp 30mg

Duloxetine Delayed Release Cap Usp 30mg
This is a description of a medication called Duloxetine, which is the generic equivalent of Cymbalta. Each capsule contains 33.7mg of Duloxetine Hydrochloride equivalent to 30mg of Duloxetine. The manufacturer is Breckenridge Pharmaceuticals, Inc. and it is packaged with an expiration date and a lot/batch number. The text also warns that it is illegal to transfer the drug to anyone other than the patient for whom it was prescribed. There are repeated mentions of "Duloxetine Delayed-Release Cap USP 30mg" with varying additional information such as quantity, insurance NDC, lot, batch, and product NDO.*
FDA Label Image

Chemical Structure (Duloxetine 01)

FDA Label Image

Figure 1 (Duloxetine 02)

FDA Label Image

Figure 2 (Duloxetine 03)

Figure 2 (Duloxetine 03)
This appears to be a graph that shows the proportion of patients experiencing relapse over time (in days) from randomization. There are three data points on the x-axis: 0, 20, and 40. The y-axis ranges from 0 to 0.2. The graph includes two lines or curves, one in blue and one in orange, that appear to represent two different treatments or groups of patients. The blue line starts at 0 and gradually increases to approximately 0.15 at 40 days. The orange line starts at 0 and remains relatively flat until around 20 days, after which it increases more rapidly to a maximum of approximately 0.2 at 40 days. There is no information regarding the specific treatments or conditions being studied.*
FDA Label Image

Figure 3 (Duloxetine 04)

FDA Label Image

Figure 4 (Duloxetine 05)

FDA Label Image

Figure 7 (Duloxetine 06)

FDA Label Image

Figure 8 (Duloxetine 07)

FDA Label Image

Figure 9 (Duloxetine 08)

FDA Label Image

Duloxetine 09

Duloxetine 09
The text describes a graph showing the percentage of patients who have improved in pain over time (1 week) from a baseline measurement, displayed on an X-axis with markings at 0, 20, and 100, and a Y-axis denoting percent improvement.*
FDA Label Image

Duloxetine Delayed-release Capsules, Usp 30mg (Duloxetine 10)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.